Vermont data ban struck down in federal court

A federal appeals court reversed a district court ruling that limited the use of prescriber-identifiable data in Vermont, signaling a victory for plaintiffs IMS Health, SDI and Wolters Kluwer Health, and setting up a possible Supreme Court showdown.
Vermont's data ban, which made it illegal to gather and sell information about a physician's prescribing habits without his or her consent, was overturned in part because it “does not directly advance the substantial state interests asserted by Vermont,” wrote District Judge John Koeltl, in the ruling.
These include “protecting the public health,” “protecting the privacy of prescriber and prescribing information,” and “ensuring [healthcare] costs are contained.
The Vermont ruling, decided by the 2nd US Circuit Court of Appeals, runs counter to a 1st US Circuit Court of Appeals decision in 2008, which examined a similar data ban in New Hampshire. The Supreme Court declined to hear plaintiff arguments about the NH data ban.
Based on the variety of court rulings in New Hampshire, Maine, and Vermont—the only three states that have passed laws banning prescriber data—the jury is still out on whether prescriber data qualifies as protected commercial speech under the First Amendment, without caveat.
“We have a split between the 1st and 2nd Circuits now, perhaps increasing the chances of a review by the US Supreme Court of these fundamental First Amendment issues,” said Cathy Betz, VP, government affairs at Wolters Kluwer Health.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.